QPS, LLC acquires a majority stake in JSW Life Sciences, enhancing its preclinical and clinical capabilities while broadening its presence in Central and Eastern Europe.

Target Company Overview

QPS, LLC, a prominent full-service contract research organization (CRO) headquartered in Newark, Delaware, has announced the acquisition of a majority stake in JSW Life Sciences GmbH, the largest independent CRO in Austria. Following the acquisition, JSW will operate under the name QPS JSW. The company boasts over 13 years of industry experience, focusing primarily on preclinical and clinical drug development services across various therapeutic areas, with a notable specialization in central nervous system (CNS) disorders, including Alzheimer's and Parkinson's diseases.

JSW has built a robust reputation due to its comprehensive service offerings, which include in vitro molecular and cellular studies, as well as advanced preclinical efficacy studies. Additionally, JSW is recognized for its access to unique biomarker technologies, positioning itself as a leader in CNS research. Its clinical operations span Phase II-IV clinical trials, ensuring extensive patient populations across Central and Eastern Europe, making it an invaluable resource for pharmaceutical and biotech companies globally.

Industry Overview

The contract research organization (CRO) industry is a critical component of the pharmaceutical and biotechnology sectors, enabling efficient drug development processes. In Central and Eastern Europe (CEE), the CRO market has witnessed substantial gr